This position offers an extraordinary opportunity to lead the launch of Bezuclastinib in the 2L Gastrointestinal Stromal Tumor (GIST) indication.
Base: $250,000 - $290,000 USD; Bonus/Equity: Target Bonus: 25%; Benefits: Not specified
Must-have
Nice-to-have
Not specified